704 related articles for article (PubMed ID: 9550290)
1. Labelling of recombinant human and native rat serotonin 5-HT1A receptors by a novel, selective radioligand, [3H]-S 15535: definition of its binding profile using agonists, antagonists and inverse agonists.
Newman-Tancredi A; Verrièle L; Chaput C; Millan MJ
Naunyn Schmiedebergs Arch Pharmacol; 1998 Mar; 357(3):205-17. PubMed ID: 9550290
[TBL] [Abstract][Full Text] [Related]
2. S 14506: novel receptor coupling at 5-HT(1A) receptors.
Milligan G; Kellett E; Dacquet C; Dubreuil V; Jacoby E; Millan MJ; Lavielle G; Spedding M
Neuropharmacology; 2001 Mar; 40(3):334-44. PubMed ID: 11166326
[TBL] [Abstract][Full Text] [Related]
3. The selective 5-HT1A antagonist radioligand [3H]WAY 100635 labels both G-protein-coupled and free 5-HT1A receptors in rat brain membranes.
Gozlan H; Thibault S; Laporte AM; Lima L; Hamon M
Eur J Pharmacol; 1995 Jan; 288(2):173-86. PubMed ID: 7720779
[TBL] [Abstract][Full Text] [Related]
4. Differential modulation by GTPgammaS of agonist and inverse agonist binding to h5-HT(1A) receptors revealed by [3H]-WAY100,635.
Newman-Tancredi A; Verrièle L; Millan MJ
Br J Pharmacol; 2001 Jan; 132(2):518-24. PubMed ID: 11159702
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological characterization of recombinant human 5-hydroxytryptamine1A receptors using a novel antagonist radioligand, [3H]WAY-100635.
Khawaja X; Ennis C; Minchin MC
Life Sci; 1997; 60(9):653-65. PubMed ID: 9048968
[TBL] [Abstract][Full Text] [Related]
6. Agonist activity of antimigraine drugs at recombinant human 5-HT1A receptors: potential implications for prophylactic and acute therapy.
Newman-Tancredi A; Conte C; Chaput C; Verrièle L; Audinot-Bouchez V; Lochon S; Lavielle G; Millan MJ
Naunyn Schmiedebergs Arch Pharmacol; 1997 Jun; 355(6):682-8. PubMed ID: 9205951
[TBL] [Abstract][Full Text] [Related]
7. S 15535 and WAY 100,635 antagonise 5-HT-stimulated [35S]GTP gamma S binding at cloned human 5-HT1A receptors.
Newman-Tancredi A; Chaput C; Verrièle L; Millan MJ
Eur J Pharmacol; 1996 Jun; 307(1):107-11. PubMed ID: 8831111
[TBL] [Abstract][Full Text] [Related]
8. Agonist and inverse agonist efficacy at human recombinant serotonin 5-HT1A receptors as a function of receptor:G-protein stoichiometry.
Newman-Tancredi A; Conte C; Chaput C; Verrièle L; Millan MJ
Neuropharmacology; 1997; 36(4-5):451-9. PubMed ID: 9225269
[TBL] [Abstract][Full Text] [Related]
9. Characterization of 5-HT1A receptor-mediated [35S]GTPgammaS binding in rat hippocampal membranes.
Alper RH; Nelson DL
Eur J Pharmacol; 1998 Feb; 343(2-3):303-12. PubMed ID: 9570480
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneity of cortical and hippocampal 5-HT1A receptors: a reappraisal of homogenate binding with 8-[3H]hydroxydipropylaminotetralin.
Nénonéné EK; Radja F; Carli M; Grondin L; Reader TA
J Neurochem; 1994 May; 62(5):1822-34. PubMed ID: 8158133
[TBL] [Abstract][Full Text] [Related]
11. Nad-299 antagonises 5-HT-stimulated and spiperone-inhibited [35S]GTPgammaS binding in cloned 5-HT1A receptors.
Jerning E; Rosqvist S; Mohell N
J Recept Signal Transduct Res; 2002; 22(1-4):483-95. PubMed ID: 12503636
[TBL] [Abstract][Full Text] [Related]
12. Correlation between low/high affinity ratios for 5-HT(1A) receptors and intrinsic activity.
Assié MB; Cosi C; Koek W
Eur J Pharmacol; 1999 Dec; 386(1):97-103. PubMed ID: 10611469
[TBL] [Abstract][Full Text] [Related]
13. Novel benzodioxopiperazines acting as antagonists at postsynaptic 5-HT1A receptors and as agonists at 5-HT1A autoreceptors: a comparative pharmacological characterization with proposed 5-HT1A antagonists.
Millan MJ; Canton H; Gobert A; Lejeune F; Rivet JM; Bervoets K; Brocco M; Widdowson P; Mennini T; Audinot V
J Pharmacol Exp Ther; 1994 Jan; 268(1):337-52. PubMed ID: 8301575
[TBL] [Abstract][Full Text] [Related]
14. NAN-190: agonist and antagonist interactions with brain 5-HT1A receptors.
Rydelek-Fitzgerald L; Teitler M; Fletcher PW; Ismaiel AM; Glennon RA
Brain Res; 1990 Nov; 532(1-2):191-6. PubMed ID: 2282513
[TBL] [Abstract][Full Text] [Related]
15. Characterisation of the binding of [3H]WAY-100635, a novel 5-hydroxytryptamine1A receptor antagonist, to rat brain.
Khawaja X; Evans N; Reilly Y; Ennis C; Minchin MC
J Neurochem; 1995 Jun; 64(6):2716-26. PubMed ID: 7760052
[TBL] [Abstract][Full Text] [Related]
16. Photoaffinity labelling and solubilization on the central 5-HT1A receptor binding site.
Gozlan H; Emerit MB; el Mestikawy S; Cossery JM; Marquet A; Besselievre R; Hamon M
J Recept Res; 1987; 7(1-4):195-221. PubMed ID: 2957498
[TBL] [Abstract][Full Text] [Related]
17. Resolution of multiple affinity states of 5-hydroxytryptamine-1A receptors labelled by [3H]-8-hydroxy-2-(di-n-propilamino) tetralin in rat hippocampal membranes.
Pesce G; Hery F
Gen Pharmacol; 1996 Jun; 27(4):723-9. PubMed ID: 8853311
[TBL] [Abstract][Full Text] [Related]
18. Agonist properties of pindolol at h5-HT1A receptors coupled to mitogen-activated protein kinase.
Millan MJ; Newman-Tancredi A; Duqueyroix D; Cussac D
Eur J Pharmacol; 2001 Jul; 424(1):13-7. PubMed ID: 11470255
[TBL] [Abstract][Full Text] [Related]
19. Differential regulation of somatodendritic serotonin 5-HT1A receptors by 2-week treatments with the selective agonists alnespirone (S-20499) and 8-hydroxy-2-(Di-n-propylamino)tetralin: microdialysis and autoradiographic studies in rat brain.
Casanovas JM; Vilaró MT; Mengod G; Artigas F
J Neurochem; 1999 Jan; 72(1):262-72. PubMed ID: 9886078
[TBL] [Abstract][Full Text] [Related]
20. Interactions of (+)- and (-)-8- and 7-hydroxy-2-(di-n-propylamino)tetralin at human (h)D3, hD2 and h serotonin1A receptors and their modulation of the activity of serotoninergic and dopaminergic neurones in rats.
Lejeune F; Newman-Tancredi A; Audinot V; Millan MJ
J Pharmacol Exp Ther; 1997 Mar; 280(3):1241-9. PubMed ID: 9067310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]